Impact of Current Volume Under High-rate Nasal Oxygen Therapy During Acute Hypoxemic Respiratory Failure de Novo (IVOXY)

De novo acute hypoxemic respiratory failure (AHRF) is associated with high overall mortality, which increases significantly with the use of orotracheal intubation. High flow nasal canula (HFNC) has turned to be the first line non-invasive oxygenation strategy aiming to avoid intubation. One of the main factors worsening lung injury and increasing mortality in invasively ventilated patients is a too high tidal volume (TV) delivered by the ventilator. Consistent data suggest that such an aggravation of respiratory lesions may occur during spontaneous ventilation if TV is too large. This phenomenon is called Patient self-inflicted lung injury (P-SILI). The effect of TV on the outcome of patients with de novo AHRF under HFNC has never been evaluated since TV is not easily accessible in patients under HFNC. Investigators hypothesized that a large TV during HFNC has an impact on the outcome. TV will be measured using chest Electrical Impedance Tomography (EIT). To calibrate the EIT data, i.e. to be able to convert changes in thoracic impedance into TV, thoracic impedance signal, flow and volume will be collected during a 4 cmH2O continuous positive airway pressure (CPAP) test, using a pneumotachograph inserted on the ventilator circuit between the mask and the Y-piece. Such a level of CPAP is supposed to reproduce the majority of the physiological effects of HFNC. Thus, EIT signal can be used to calculate TV during HFNC since it remains reliable even when the positive expiratory pressure changes.

A secondary objective is to quantify a respiratory distress index. This quantification will be recorded by respiratory inductance plethysmography (RIP), obtained using two elastic bands equipped with a sensor sensitive to their stretching, one positioned at the level of the thorax, the other at the level of the abdomen. The stretching changes of the two bands during the respiratory cycle allow evaluating their possible asynchronism by calculating the phase angle Investigators want to be able to evaluate up to 6 predictors of HFNC failure in this research with an effect size of 0.15, α risk of 0.05, and a power of 0.8. A number of 55 participants is required. Investigators plan to include 60 patients due to potential withdrawal of consent and/or unusable data.

Study Overview

Study Type

Interventional

Enrollment (Anticipated)

60

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Créteil, France, 94010
        • Assistance Publique Hôpitaux de Paris - CHU Henri Mondor - Créteil

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Age ≥ 18 years old
  • HFNC initiated as part of the care
  • Respiratory rate > 25 / minute
  • PaO2/FiO2 ratio < 300 mm Hg
  • PaCO2 < 45 mm Hg
  • Affiliated with a social security system
  • Informed consent signed by the patient, trusted person or family member if the patient is unable to consent

Exclusion Criteria:

  • Acute cardiogenic pulmonary edema
  • Underlying chronic respiratory disease
  • Asthma exacerbation
  • Chronic obstructive pulmonary disease Exacerbation
  • Hemodynamic instability, defined as systolic arterial blood pressure < 90 mm Hg or mean arterial blood pressure < 65 mm Hg or the use of vasopressors
  • Glasgow Coma Score <= 12
  • Contraindication to CPAP (maxillofacial surgery, facial trauma)
  • Refusal of the patient to perform the CPAP test
  • Need for emergency intubation according to the clinician in charge of the patient
  • Patient protected by law
  • Pregnancy or breastfeeding woman

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: DIAGNOSTIC
  • Allocation: NA
  • Interventional Model: SINGLE_GROUP
  • Masking: NONE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
EXPERIMENTAL: Experimental
Every adult patient admitted to the medical intensive care unit for de novo acute hypoxemic respiratory failure, and placed under hign flow nasal canula (HFNC). Inclusion and exclusion criterion are listed elsewhere.
After information and consent, patients under HFNC for de novo acute hypoxemic respiratory failure will undergo a ten minutes 4cmH2O continuous positive airway pressure(CPAP) test while monitored with 1)chest Electrical Impedance Tomography (EIT) 2) a pneumotachograph inserted on the ventilator circuit between the mask and the Y-piece and connected to a differential pressure sensor, and 3) respiratory inductance plethysmography (RIP). Airway flow signal will be acquired using an analog/digital converter and stored for further analysis with acknowledge software. This will allow converting EIT data into tidal volume (TV), and estimating TV under HFNC. RIP signals will allow evaluating asynchronism between chest and abdomen by calculating the phase angle, thus quantifying respiratory distress. Patients monitored with an arterial catheter, arterial blood gas measurements will be done during CPAP and HFNC. These measures will be collected the first day of HFNC, and everyday up to three days

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Failure of high flow nasal canula (HFNC) at day 28
Time Frame: Day 28
Failure of HFNC is defined as death or need for invasive mechanical ventilation
Day 28

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Tidal volume under high flow nasal canula (HFNC)
Time Frame: Day 0, Day 1 and Day 2
Tidal volume will be measured using chest Electrical Impedance Tomography (EIT)
Day 0, Day 1 and Day 2
Phase angle computed by respiratory inductance plethysmography (RIP)
Time Frame: Day 0, Day 1 and Day 2
Phase angle will be measured by respiratory inductance plethysmography
Day 0, Day 1 and Day 2
Respiratory rate
Time Frame: Day 0, Day 1 and Day 2
respiratory rate will be measured at each evaluation
Day 0, Day 1 and Day 2
pH under high flow nasal canula (HFNC)
Time Frame: Day 0, Day 1 and Day 2
pH will be measured via Blood gases
Day 0, Day 1 and Day 2
PaO2 under high flow nasal canula (HFNC)
Time Frame: Day 0, Day 1 and Day 2
PaO2 will be measured via Blood gases
Day 0, Day 1 and Day 2
PaCO2 under high flow nasal canula (HFNC)
Time Frame: Day 0, Day 1 and Day 2
PaCO2 will be measured via Blood gases
Day 0, Day 1 and Day 2
SaO2 under high flow nasal canula (HFNC)
Time Frame: Day 0, Day 1 and Day 2
SaO2 will be measured via Blood gases
Day 0, Day 1 and Day 2
Regional tidal volume.
Time Frame: Day 0, Day 1 and Day 2
computed by Electrical Impedance Tomography
Day 0, Day 1 and Day 2
Mortality
Time Frame: Day 28, Day90
Mortality at Day 28, Day 90
Day 28, Day90

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Guillaume CARTEAUX, Doctor, Assistance Publique Hôpitaux de Paris - CHU Henri Mondor - Créteil

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ANTICIPATED)

June 1, 2019

Primary Completion (ANTICIPATED)

June 3, 2021

Study Completion (ANTICIPATED)

September 1, 2021

Study Registration Dates

First Submitted

March 26, 2019

First Submitted That Met QC Criteria

April 15, 2019

First Posted (ACTUAL)

April 18, 2019

Study Record Updates

Last Update Posted (ACTUAL)

May 16, 2019

Last Update Submitted That Met QC Criteria

May 14, 2019

Last Verified

March 1, 2019

More Information

Terms related to this study

Other Study ID Numbers

  • APHP180138

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

DATAS ARE OWN BY ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS, PLEASE CONTACT SPONSOR FOR FURTHER INFORMATION

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Acute Hypoxemic Respiratory Failure

Clinical Trials on Assessment of tidal volume using Electrical Impedance Tomography (EIT) during high flow nasal canula(HFNC)

Subscribe